Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?

Johnson & Johnson is presented as the stronger long-term dividend holding, having raised its annual payout for 64 consecutive years to $5.36 per share, although its 2.0% forward yield is below Kenvue's 4.71%. J&J faces a proposed $5.5B ovarian-cancer talc settlement and had reserved roughly $3.7B for talc liabilities as of Q2 2026, creating a material cash-use risk. Kenvue trades at about 21x earnings and yields 4.71%, but its dividend outlook is uncertain because Kimberly-Clark's pending cash-and-stock acquisition values the company at approximately $48.7B.

Analysis

The clean relative-value expression is not JNJ versus KVUE, but JNJ versus the post-deal KMB capital structure. JNJ's consumer separation has concentrated earnings in franchises with materially better pricing and innovation optionality, while its legal overhang creates an event-driven valuation discount rather than a recurring operating-cost issue. A final talc resolution would remove a key multiple cap and free management to redeploy incremental cash toward bolt-on medtech and oncology assets; adverse mesothelioma verdict trends, however, could keep the discount embedded for several quarters.

KVUE's quoted yield is not a durable standalone-screening signal because the relevant future payout policy, leverage capacity, and buyback priority will be set by KMB after closing. KMB's strategic logic depends on extracting procurement, manufacturing, and overhead synergies from mature brands without sacrificing marketing support; that raises the probability of near-term margin action but also increases the risk that volume elasticity appears with a lag. The less obvious loser is KMB equity if financing costs remain elevated: consumer-health cash flows are stable, but a leverage-led deal can constrain dividend-growth and multiple expansion precisely when staples investors own the stock for balance-sheet conservatism.

Near term, KVUE should trade primarily on deal spread, regulatory timing, and KMB share-price exposure rather than underlying quarterly demand. Over 6-18 months, JNJ has the superior catalyst set if pharmaceutical pipeline execution and medtech procedure growth offset litigation cash outflows; the contrarian point is that a headline settlement may be more bullish than feared if it converts an unbounded liability narrative into a known, financeable obligation. This thesis is falsified by a material litigation reserve increase, a failed settlement participation threshold followed by escalating verdicts, or a meaningful reduction in JNJ's operating-cash-flow outlook.

Key Decisions for Investors

• Initiate a 6-12 month long JNJ / short XLV-neutralized healthcare peer basket only on litigation-driven weakness; target a 10-15% rerating if settlement finality and unchanged operating guidance remove the overhang. Exit if talc reserves rise materially or management cuts its cash-flow outlook.
• Do not underwrite KVUE as a standalone dividend compounder. Treat it as merger-arbitrage exposure only after confirming the cash/share consideration, collar mechanics, expected close date, financing conditions, and regulatory remedies; without those terms, the spread cannot be converted into a risk-adjusted recommendation.
• For investors requiring consumer-staples exposure, wait for KMB post-close financing disclosures before adding. A long KMB position is attractive only if pro forma net leverage, synergy targets, and dividend coverage support deleveraging within 24-36 months; otherwise prefer a sector-neutral short KMB versus long XLP as integration costs emerge.
• Set event alerts for JNJ's talc settlement participation outcome and quarterly litigation-reserve changes over the next 1-3 months; these are more consequential to the equity multiple than incremental dividend growth.